GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Cyanotech Corp (OTCPK:CYAN) » Definitions » Debt-to-EBITDA

Cyanotech (Cyanotech) Debt-to-EBITDA : -8.52 (As of Dec. 2023)


View and export this data going back to 1993. Start your Free Trial

What is Cyanotech Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Cyanotech's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $6.33 Mil. Cyanotech's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $4.88 Mil. Cyanotech's annualized EBITDA for the quarter that ended in Dec. 2023 was $-1.32 Mil. Cyanotech's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -8.52.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Cyanotech's Debt-to-EBITDA or its related term are showing as below:

CYAN' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -13.54   Med: 3.2   Max: 10.43
Current: -6.08

During the past 13 years, the highest Debt-to-EBITDA Ratio of Cyanotech was 10.43. The lowest was -13.54. And the median was 3.20.

CYAN's Debt-to-EBITDA is ranked worse than
100% of 1425 companies
in the Consumer Packaged Goods industry
Industry Median: 2.13 vs CYAN: -6.08

Cyanotech Debt-to-EBITDA Historical Data

The historical data trend for Cyanotech's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cyanotech Debt-to-EBITDA Chart

Cyanotech Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -7.46 3.83 2.98 1.91 -13.54

Cyanotech Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.57 -3.85 -4.21 -26.55 -8.52

Competitive Comparison of Cyanotech's Debt-to-EBITDA

For the Packaged Foods subindustry, Cyanotech's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cyanotech's Debt-to-EBITDA Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Cyanotech's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Cyanotech's Debt-to-EBITDA falls into.



Cyanotech Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Cyanotech's Debt-to-EBITDA for the fiscal year that ended in Mar. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(5.892 + 5.275) / -0.825
=-13.54

Cyanotech's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(6.326 + 4.883) / -1.316
=-8.52

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


Cyanotech  (OTCPK:CYAN) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Cyanotech Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Cyanotech's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Cyanotech (Cyanotech) Business Description

Traded in Other Exchanges
N/A
Address
73-4460 Queen Kaahumanu Highway, Suite 102, Kailua-Kona, HI, USA, 96740
Cyanotech Corp is engaged in the production of natural products derived from microalgae for the nutritional supplements market. The company's products include BioAstin Hawaiian Astaxanthin and Hawaiian Spirulina Pacifica is a dietary supplement used for extra energy, a strengthened immune system, cardiovascular benefits, and as a source of antioxidant carotenoids. BioAstin Hawaiian Astaxanthin is a dietary antioxidant shown to support and maintain the body's natural inflammatory response, enhance skin, and support eye and joint health. It derives maximum revenue from the Packaged product and geographically from the United States.
Executives
Kakuk Collette Nicole officer: Chief Strategic Comml Officer 73-4460 QUEEN KAAHUMANU HWY SUITE 102, KAILUA-KONA HI 96740
Michael A / Davis director, 10 percent owner 1621 JUANITA LANE, TIBURON CA 94920
Angela May Mcelwee director 73-4460 QUEEN KAAHUMANU HWY SUITE 102, KAILUA-KONA HI 96740
Charles Jason Hartmann officer: VP, Sales & Marketing 73-4460 QUEEN KAAHUMANU HWY SUITE 102, KAILUA-KONA HI 96740
Glenn Jensen officer: VP-Operations 73-4460 QUEEN KAAHUMANU HWY #102, KAILUA-KONA HI 96740
Jennifer M. Johansen officer: VP of Quality 73-4460 QUEEN KAAHUMANU HWY #102, KAILUA KONA HI 96740
Walter Bennett Menzel director 45 MOUNT TIBURON ROAD, TIBURON CA 94920
Felicia I Ladin officer: CFO, VP Fin & Admin, Treasurer 26 CORPORATE CIRCLE, ALBANY NY 12203
Matthew Keith Custer officer: Vice President, Gen Mgr 73-4460 QUEEN KAAHUMANU HWY #102, KAILUA KONA HI 96740
Amy Beth Nordin officer: VP, HR, Secretary 73-4460 QUEEN KAAHUMANU HWY. SUITE 102, KAILUA-KONA HI 96740
Brian Brett Orlopp officer: CFO, VP, Treasurer, Secretary 73-4460 QUEEN KAAHUMANU HWY #102, KAILUA KONA CA 96740
Gerald J Watts officer: COO 2530 RED HILL AVE, SANTA ANA CA 92705
Mawae Morton officer: President 7473 MAKA'A STREET, HONOLULU HI 96825
Nancy E Katz director CALYPTE BIOMEDICAL CORP, 1265 HARBOR BAY PKWY, ALAHEDA CA 94502
David M Mulder director 21771 CALATRAVA, MISSION VIEJO CA 92692